Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$7.70 +0.9%	$6.95	$4.79 ▼ $8.58	$29.98B	0.85	527,610 shs	856,182 shs
JNJ Johnson & Johnson	$152.27 +0.6%	$153.99	$140.68 ▼ $169.99	$364.09B	0.42	8.00 million shs	9.54 million shs
PFE Pfizer	$24.31 +1.1%	$23.33	$20.92 ▼ $31.54	$136.62B	0.57	41.29 million shs	34.39 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	+0.92%	-0.13%	+10.00%	+25.82%	+8.30%
JNJ Johnson & Johnson	+0.62%	-0.08%	-0.56%	-5.80%	+2.12%
PFE Pfizer	+1.10%	+1.25%	+4.16%	-3.52%	-14.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	4.9398 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
PFE Pfizer	4.8713 of 5 stars	2.3	4.0	4.2	4.3	2.4	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.25	Buy	N/A	N/A
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	12.23% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.00% Upside

Current Analyst Ratings Breakdown

Latest PFE, JNJ, and BAYRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/28/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/24/2025	JNJ Johnson & Johnson	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $165.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$50.44B	0.60	$3.81 per share	2.02	$8.82 per share	0.87
JNJ Johnson & Johnson	$88.82B	4.12	$13.21 per share	11.53	$29.69 per share	5.13
PFE Pfizer	$63.63B	2.17	$4.41 per share	5.51	$15.62 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$2.76B	-$0.92	N/A	6.75	N/A	-7.26%	13.94%	4.09%	8/5/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	16.94	13.75	2.29	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.61	8.02	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest PFE, JNJ, and BAYRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.26%	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.42%	N/A	57.84%	64 Years
PFE Pfizer	$1.72	7.08%	N/A	124.64%	16 Years

Latest PFE, JNJ, and BAYRY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.07	1.25	0.79
JNJ Johnson & Johnson	0.49	1.26	1.03
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
JNJ Johnson & Johnson	69.55%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
JNJ Johnson & Johnson	0.16%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	92,815	3.93 billion	N/A	Not Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, JNJ, and BAYRY Headlines

Recent News About These Companies

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

June 24 at 6:46 PM | zacks.com

Pfizer’s Promising Phase 1B Trial for Multiple Myeloma: Key Insights for Investors

June 24 at 4:28 PM | msn.com

Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?

June 24 at 11:26 AM | zacks.com

My 5 Favorite Dirt Cheap Stocks to Buy Right Now

June 24 at 7:10 AM | fool.com

WoodTrust Financial Corp Sells 149,391 Shares of Pfizer Inc. (NYSE:PFE)

June 24 at 6:02 AM | marketbeat.com

Spirepoint Private Client LLC Has $555,000 Holdings in Pfizer Inc. (NYSE:PFE)

June 24 at 5:55 AM | marketbeat.com

Consolidated Portfolio Review Corp Boosts Holdings in Pfizer Inc. (NYSE:PFE)

June 24 at 5:38 AM | marketbeat.com

Lazari Capital Management Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)

June 24 at 5:30 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by AssuredPartners Investment Advisors LLC

June 24 at 5:21 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Asset Management One Co. Ltd.

June 24 at 5:21 AM | marketbeat.com

Oppenheimer Asset Management Inc. Acquires 32,203 Shares of Pfizer Inc. (NYSE:PFE)

June 24 at 4:48 AM | marketbeat.com

Pfizer’s Dividend Backed by Strong Free Cash Flow

June 24 at 12:13 AM | insidermonkey.com

The 5 Most Interesting Analyst Questions From Pfizer’s Q1 Earnings Call

June 23 at 10:36 AM | msn.com

Oppenheimer & Co. Inc. Grows Holdings in Pfizer Inc. (NYSE:PFE)

June 23 at 7:20 AM | marketbeat.com

Jmac Enterprises LLC Sells 20,239 Shares of Pfizer Inc. (NYSE:PFE)

June 23 at 5:42 AM | marketbeat.com

Live Oak Private Wealth LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

June 23 at 5:30 AM | marketbeat.com

10 Stocks That Pay $100 or More in Dividends

June 23 at 5:30 AM | fool.com

Pfizer Inc. (NYSE:PFE) Shares Sold by ORG Partners LLC

June 23 at 4:05 AM | marketbeat.com

Cambridge Investment Research Advisors Inc. Acquires 64,277 Shares of Pfizer Inc. (NYSE:PFE)

June 22 at 7:25 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Has $4.18 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 22 at 6:20 AM | marketbeat.com

Heartland Bank & Trust Co Buys New Shares in Pfizer Inc. (NYSE:PFE)

June 22 at 5:30 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, JNJ, and BAYRY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$7.70 +0.07 (+0.92%)

As of 06/24/2025 03:57 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Johnson & Johnson NYSE:JNJ

$152.27 +0.95 (+0.63%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$151.53 -0.74 (-0.48%)

As of 06/24/2025 08:00 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Pfizer NYSE:PFE

$24.30 +0.28 (+1.14%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$24.30 -0.01 (-0.04%)

As of 06/24/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time